Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with revenue reaching approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The company reported a loss attributable to shareholders of approximately HKD 0.9 million, which is a substantial reduction of about 95% compared to the previous year [1] - The increase in revenue is primarily attributed to the rising demand in the health products market and improved operational efficiency in supply chain services, underscoring the effectiveness of the company's strategic focus on these core business areas [1] Group 2 - The board of directors noted that the significant improvement in the group's financial performance this year is mainly due to several net impacts, including a gross profit increase of approximately HKD 9.2 million or 184% year-on-year due to business improvements [1] - The company has strengthened cost control over administrative and operational expenses [1] - The company recorded capitalized loan income of approximately HKD 3.9 million this year, which contributed to a reduction in financing costs due to the capitalized loans [1]

董事会认为集团于本年度财务业绩显著改善乃主要由于以下各项的净影响，其中包括：(i)由于业务改 善，毛利同比增长约920万港元或184%;(ii)加强行政及营运开支的成本控制;(iii)于本年度，贷款资本化 收益约390万港元;及(iv)由于本年度的贷款资本化，融资成本减少。 国药科技股份(08156)公布截至2025年6月30日止年度业绩，收入约6130万港元，同比增加约48%。公司 拥有人应占亏损约90万港元，同比大幅减少约95%。每股亏损0.19港仙。 公告称，收入增长主要由于大健康产品市场需求增加及供应链服务营运效率提高，突显公司对该等核心 业务领域的战略重点的有效性。 ...